C2orf37 Inhibitors
Chemical inhibitors of C2orf37 can impede its function through several mechanistic pathways, primarily through the disruption of kinase activities that C2orf37 may rely on for its cellular functions. Alsterpaullone, Olomoucine, Roscovitine, and Indirubin-3'-monoxime are notable for their ability to inhibit cyclin-dependent kinases (CDKs). These CDKs are integral to cell cycle progression, and their inhibition can arrest the cell cycle in phases where C2orf37 is active. For instance, if C2orf37 is involved in DNA replication or repair during the S phase, halting the cycle could prevent C2orf37 from participating in these processes. Similarly, Harmine's inhibition of DYRK1A can disrupt neuronal development and other cellular processes that may rely on the functional integrity of C2orf37.
Further down the signaling cascade, 5-Iodotubercidin disrupts adenosine kinase activity, leading to elevated adenosine levels and subsequent interference with adenosine-responsive pathways. The JNK pathway, targeted by SP600125, is another site of intervention where the inhibition can obstruct the signaling that regulates C2orf37's role in stress or apoptosis-related pathways. SB203580 and PD98059 target the MAPK pathway, with the former inhibiting p38 MAPK and the latter targeting MEK. These inhibitors can prevent the activation of downstream targets of MAPK signaling, which could include C2orf37. LY294002 and Wortmannin both inhibit PI3K, curtailing the PI3K/Akt pathway and potentially impeding any C2orf37-associated processes that depend on this signaling for survival, proliferation, or metabolism.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs) which are crucial for cell cycle regulation. Inhibition of CDKs can lead to the functional inhibition of C2orf37 if C2orf37's activity is cell cycle-dependent. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor that can prevent cell cycle progression. It can functionally inhibit C2orf37 by halting cellular processes that C2orf37 may be involved in. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine, a purine analogue, selectively inhibits CDKs. By blocking CDK-dependent pathways, it can lead to the inhibition of C2orf37 if the protein is associated with these pathways. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is a potent inhibitor of CDKs and GSK-3β. It can inhibit C2orf37 by disrupting cellular processes regulated by these kinases. | ||||||
Harmine | 442-51-3 | sc-202644 sc-202644A sc-202644B sc-202644C sc-202644D sc-202644E sc-202644F | 250 mg 500 mg 1 g 10 g 50 g 100 g 500 g | $53.00 $104.00 $126.00 $551.00 $1467.00 $2611.00 $11455.00 | 2 | |
Harmine is an inhibitor of DYRK1A, a kinase involved in neuronal development and other cellular processes. C2orf37 inhibition can occur through the disruption of DYRK1A-mediated pathways. | ||||||
Nefiracetam | 77191-36-7 | sc-205766 sc-205766A | 100 mg 250 mg | $131.00 $146.00 | 1 | |
5-Iodotubercidin inhibits adenosine kinases, which can lead to increased levels of adenosine disrupting signaling pathways that could inhibit C2orf37. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK pathway, which can lead to inhibition of C2orf37 by interfering with the JNK signaling that may regulate C2orf37 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, it can interfere with signaling processes that C2orf37 may be involved in, leading to its inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can prevent the activation of the MAPK/ERK pathway. This can lead to functional inhibition of C2orf37 if it is part of this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and by blocking PI3K/Akt signaling, it can lead to the inhibition of C2orf37 if the protein operates within this pathway. | ||||||